Illumina, Inc. logo

Illumina, Inc. (ILMN)

Market Closed
27 Feb, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
134. 46
+7.06
+5.54%
$
17.99B Market Cap
- P/E Ratio
- Div Yield
3,136,081 Volume
0.66 Eps
$ 127.4
Previous Close
Day Range
127.01 134.75
Year Range
68.7 155.53
Want to track ILMN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ILMN earnings report is expected in 58 days (28 Apr 2026)
Why Illumina (ILMN) is a Top Value Stock for the Long-Term

Why Illumina (ILMN) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 week ago
Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy?

Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 2 weeks ago
Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips

Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips

ILMN tops Q4 EPS and revenue estimates, posts 42% profit jump, but shares slide 10% on margin concerns despite 2026 growth outlook.

Zacks | 2 weeks ago
Unlocking Illumina (ILMN) International Revenues: Trends, Surprises, and Prospects

Unlocking Illumina (ILMN) International Revenues: Trends, Surprises, and Prospects

Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Zacks | 2 weeks ago
Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript

Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript

Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript

Seekingalpha | 3 weeks ago
Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 3 weeks ago
Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates

Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates

Illumina (ILMN) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $0.86 per share a year ago.

Zacks | 3 weeks ago
Insights Into Illumina (ILMN) Q4: Wall Street Projections for Key Metrics

Insights Into Illumina (ILMN) Q4: Wall Street Projections for Key Metrics

Beyond analysts' top-and-bottom-line estimates for Illumina (ILMN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.

Zacks | 3 weeks ago
ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance

ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance

Illumina eyes Q4 growth on NovaSeq X momentum, new multiomic launches and stronger sequencing demand despite China export limits.

Zacks | 3 weeks ago
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 month ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks | 1 month ago
Illumina's New Connected Multiomics Platform Set to Boost Its Stock

Illumina's New Connected Multiomics Platform Set to Boost Its Stock

ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.

Zacks | 1 month ago
Loading...
Load More